6 News & Press Releases found
Abologix News
-
Abologix wins CHF 150,000 to develop targeted antibodies for cancer patients
Abologix develops a new therapeutic option to treat lymphoma patients who have become resistant to conventional treatments. The Geneva-based biotech startup is a spin-out from the laboratories at the University of Geneva (UNIGE) and the Geneva ...
-
ABOLOGIX awarded a two year Innosuisse Innovation
Abologix has been granted a 2 year Innosuisse Innovation project in collaboration with the University Hospital of Geneva (HUG). The HUG will be the research partner and Abologix the implementation partner.The collaboration plans to study the ...
-
One of the top 50 start ups in french-speaking Switzerland
Abologix has received recognition in “Bilan” as one of the most promising swiss start-ups in the french speaking cantons of Switzerland. The company has been invited to address a group of potential investors in a future meeting to be ...
-
Abologix obtains positive pre-clinical proof-of-concept results with its monoclonal antibody H225
Abologix has obtained impressive data with its anti-JAM-C recombinant monoclonal antibody rH225 in an animal Mantle Cell Lymphoma (MCL) NOD/SCID mouse model. In this study the efficacy of rH225 was tested by assessing: the delayed mortality ...
-
License agreement with Research Development Foundation for two monoclonal antibodies for oncology
Abologix has entered into an exclusive, worldwide in-license agreement with Research Development Foundation for two monoclonal antibodies for oncological indications that were developed at the University of Geneva with funding from Institut Clayton ...
-
ABOLOGIX founded in Geneva, Switzerland
Abologix was launched today, and it is the newest addition to the biotechnology ecosystem in the city of Geneva (Switzerland). The three founders of Abologix are Dr.Ignacio Faus, Prof. Beat Imhof and Prof. Thomas Matthes.The company intends to ...